Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
(Hyaluronidase (recombinant human) + pembrolizumab) by Merck for Metastatic Melanoma: Likelihood of Approval
(Hyaluronidase (recombinant human) + pembrolizumab) is under clinical development by Merck and currently in Phase II for Metastatic Melanoma. According...
(Hyaluronidase (recombinant human) + pembrolizumab) by Merck for Solid Tumor: Likelihood of Approval
(Hyaluronidase (recombinant human) + pembrolizumab) is under clinical development by Merck and currently in Phase I for Solid Tumor. According...
(Hyaluronidase (recombinant human) + pembrolizumab) by Merck for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
(Hyaluronidase (recombinant human) + pembrolizumab) is under clinical development by Merck and currently in Phase II for Primary Mediastinal B-Cell...